Abstract

N-acetylaspartate (NAA) is a highly abundant brain metabolite. Aberrant NAA concentrations have been detected in many pathological conditions and although the function of NAA has been extensively investigated in the brain it is still controversial. Only recently, a role of NAA has been reported outside the brain. In brown adipocytes, which show high expression of the NAA-producing and the NAA-cleaving enzyme, the metabolism of NAA has been implicated in lipid synthesis and histone acetylation. Increased expression of N-acetyltransferase 8-like (Nat8l, the gene encoding the NAA synthesizing enzyme) induces de novo lipogenesis and the brown adipocyte phenotype. Accordingly silencing of aspartoacylase, the NAA-cleaving enzyme, reduced brown adipocyte differentiation mechanistically by decreasing histone acetylation and gene transcription. Notably, the expression of Nat8l and the amount of NAA were also shown to be increased in several tumors and inversely correlate with patients’ survival. Additionally, Nat8l silencing reduced cell proliferation in tumor and non-tumor cells, while NAA supplementation could rescue it. However, the mechanism behind has not yet been clarified. It remains to be addressed whether NAA per se and/or its catabolism to acetate and aspartate, metabolites that have both been implicated in tumor growth, are valuable targets for future therapies.

Highlights

  • N-acetylaspartate (NAA) is the second most abundant brain metabolite with concentrations around 10 mM [1]

  • NAA has been suggested as acetyl-CoA source for myelin lipid synthesis in oligodendrocytes during brain development and loss-of-function mutations of Aspa lead to hypomyelination as well as NAA accumulation in the central nervous system (CNS) [3, 4]

  • Even though disruption of NAA metabolism leads to clear effects in human and mice, to this day, the question whether NAA itself or its breakdown to acetate and aspartate is essential for CNS awaits to be answered

Read more

Summary

Introduction

N-acetylaspartate (NAA) is the second most abundant brain metabolite with concentrations around 10 mM [1]. NAA has been suggested as acetyl-CoA source for myelin lipid synthesis in oligodendrocytes during brain development and loss-of-function mutations of Aspa lead to hypomyelination as well as NAA accumulation in the central nervous system (CNS) [3, 4].

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.